{"pmid":32321633,"title":"Implications of COVID-19 for the management of patients with inflammatory rheumatic diseases.","text":["Implications of COVID-19 for the management of patients with inflammatory rheumatic diseases.","Joint Bone Spine","Richez, Christophe","Lazaro, Estibaliz","Lemoine, Mael","Truchetet, Marie-Elise","Schaeverbeke, Thierry","32321633"],"journal":"Joint Bone Spine","authors":["Richez, Christophe","Lazaro, Estibaliz","Lemoine, Mael","Truchetet, Marie-Elise","Schaeverbeke, Thierry"],"date":"2020-04-24T11:00:00Z","year":2020,"_id":"32321633","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.jbspin.2020.03.010","keywords":["covid-19","health system","inflammatory rheumatic diseases","treatment"],"source":"PubMed","topics":["Prevention"],"weight":1,"_version_":1664895932754296832,"score":8.518259,"similar":[{"pmid":32201335,"pmcid":"PMC7164881","title":"Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the Coronavirus Disease 2019 (COVID-19) Pandemic.","text":["Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the Coronavirus Disease 2019 (COVID-19) Pandemic.","The coronavirus disease-2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 that has significant implications for the cardiovascular care of patients. First, those with COVID-19 and preexisting cardiovascular disease (CVD) have an increased risk of severe disease and death. Second, infection has been associated with multiple direct and indirect cardiovascular complications including acute myocardial injury, myocarditis, arrhythmias and venous thromboembolism. Third, therapies under investigation for COVID-19 may have cardiovascular side effects. Fourth, the response to COVID-19 can compromise the rapid triage of non-COVID-19 patients with cardiovascular conditions. Finally, the provision of cardiovascular care may place health care workers in a position of vulnerability as they become host or vectors of virus transmission. We hereby review the peer-reviewed and preprint literature pertaining to cardiovascular considerations related to COVID-19 and highlight gaps in knowledge that require further study pertinent to patients, health care workers, and health systems.","J Am Coll Cardiol","Driggin, Elissa","Madhavan, Mahesh V","Bikdeli, Behnood","Chuich, Taylor","Laracy, Justin","Bondi-Zoccai, Giuseppe","Brown, Tyler S","Nigoghossian, Caroline Der","Zidar, David A","Haythe, Jennifer","Brodie, Daniel","Beckman, Joshua A","Kirtane, Ajay J","Stone, Gregg W","Krumholz, Harlan M","Parikh, Sahil A","32201335"],"abstract":["The coronavirus disease-2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 that has significant implications for the cardiovascular care of patients. First, those with COVID-19 and preexisting cardiovascular disease (CVD) have an increased risk of severe disease and death. Second, infection has been associated with multiple direct and indirect cardiovascular complications including acute myocardial injury, myocarditis, arrhythmias and venous thromboembolism. Third, therapies under investigation for COVID-19 may have cardiovascular side effects. Fourth, the response to COVID-19 can compromise the rapid triage of non-COVID-19 patients with cardiovascular conditions. Finally, the provision of cardiovascular care may place health care workers in a position of vulnerability as they become host or vectors of virus transmission. We hereby review the peer-reviewed and preprint literature pertaining to cardiovascular considerations related to COVID-19 and highlight gaps in knowledge that require further study pertinent to patients, health care workers, and health systems."],"journal":"J Am Coll Cardiol","authors":["Driggin, Elissa","Madhavan, Mahesh V","Bikdeli, Behnood","Chuich, Taylor","Laracy, Justin","Bondi-Zoccai, Giuseppe","Brown, Tyler S","Nigoghossian, Caroline Der","Zidar, David A","Haythe, Jennifer","Brodie, Daniel","Beckman, Joshua A","Kirtane, Ajay J","Stone, Gregg W","Krumholz, Harlan M","Parikh, Sahil A"],"date":"2020-03-24T11:00:00Z","year":2020,"_id":"32201335","week":"202013|Mar 23 - Mar 29","doi":"10.1016/j.jacc.2020.03.031","keywords":["cardiovascular therapy","coronavirus","health system"],"source":"PubMed","topics":["Prevention"],"weight":1,"_version_":1664639760403005440,"score":78.18657},{"pmid":32316337,"title":"COVID-19 Pandemic and the Crisis of Health Systems: The Experience of the Apulia Cancer Network and of the Comprehensive Cancer Center Istituto Tumori \"Giovanni Paolo II\" of Bari.","text":["COVID-19 Pandemic and the Crisis of Health Systems: The Experience of the Apulia Cancer Network and of the Comprehensive Cancer Center Istituto Tumori \"Giovanni Paolo II\" of Bari.","On 11 March 2020, the World Health Organization declared a new disease caused by a novel virus characterized by rapid human-to-human transmission and named severe acute respiratory syndrome coronoavirus-2 (SARS-CoV-2) a pandemic. In terms of this ongoing international scenario, we report the situation in Apulia, a region of southern Italy that, as of April 2, has not yet been overwhelmed by this health emergency. In particular, we consider the care models that have been adopted, especially those that manage the requests of cancer patients.","Int J Environ Res Public Health","Silvestris, Nicola","Moschetta, Antonio","Paradiso, Angelo","Delvino, Antonio","32316337"],"abstract":["On 11 March 2020, the World Health Organization declared a new disease caused by a novel virus characterized by rapid human-to-human transmission and named severe acute respiratory syndrome coronoavirus-2 (SARS-CoV-2) a pandemic. In terms of this ongoing international scenario, we report the situation in Apulia, a region of southern Italy that, as of April 2, has not yet been overwhelmed by this health emergency. In particular, we consider the care models that have been adopted, especially those that manage the requests of cancer patients."],"journal":"Int J Environ Res Public Health","authors":["Silvestris, Nicola","Moschetta, Antonio","Paradiso, Angelo","Delvino, Antonio"],"date":"2020-04-23T11:00:00Z","year":2020,"_id":"32316337","week":"202017|Apr 20 - Apr 26","doi":"10.3390/ijerph17082763","keywords":["covid-19","cancer patient","health system","pandemic"],"source":"PubMed","topics":["Prevention"],"weight":1,"locations":["Apulia","Italy","Bari"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"_version_":1664815087803695105,"score":72.18848},{"pmid":32303821,"title":"[A cross sectional study on patients with inflammatory rheumatic diseases in terms of their compliance to their immunsuppressive medication during COVID-19 pandemic].","text":["[A cross sectional study on patients with inflammatory rheumatic diseases in terms of their compliance to their immunsuppressive medication during COVID-19 pandemic].","The current COVID-19 pandemic inherits an unprecedented challenge for the treating rheumatologists. On the one hand, antirheumatic drugs can increase the risk of infection and potentially deteriorate the course of an infection. On the other hand, an active inflammatory rheumatic disease can also increase the risk for an infection. In the recommendations of the German Society for Rheumatology (www.dgrh.de), it is recommended that our patients continue the antirheumatic therapy to maintain remission or low state of activity despite the pandemic. In this study, patients with inflammatory rheumatic disease were asked in the first weeks of the pandemic on their opinion of their immunomodulating therapy. The result shows that over 90% of the patients followed the recommendation of the rheumatologist to continue the antirheumatic therapy, and only a small percentage of the patients terminated the therapy on their own. This result was independent of the individual anti-rheumatic therapy. Taken together, the results of this study illustrate not only the trustful patient-physician partnership in a threatening situation but also the high impact of state-of-the art recommendations by the respective scientific society.","Z Rheumatol","Schmeiser, T","Broll, M","Dormann, A","Frabel, C","Hermann, W","Hudowenz, O","Keil, F","Muller-Ladner, U","Ozden, F","Pfeiffer, U","Saech, J","Schwarting, A","Stapfer, G","Steinchen, N","Storck-Muller, K","Strunk, J","Thiele, A","Triantafyllias, K","Wassenberg, S","Wilden, E","Hasseli, R","32303821"],"abstract":["The current COVID-19 pandemic inherits an unprecedented challenge for the treating rheumatologists. On the one hand, antirheumatic drugs can increase the risk of infection and potentially deteriorate the course of an infection. On the other hand, an active inflammatory rheumatic disease can also increase the risk for an infection. In the recommendations of the German Society for Rheumatology (www.dgrh.de), it is recommended that our patients continue the antirheumatic therapy to maintain remission or low state of activity despite the pandemic. In this study, patients with inflammatory rheumatic disease were asked in the first weeks of the pandemic on their opinion of their immunomodulating therapy. The result shows that over 90% of the patients followed the recommendation of the rheumatologist to continue the antirheumatic therapy, and only a small percentage of the patients terminated the therapy on their own. This result was independent of the individual anti-rheumatic therapy. Taken together, the results of this study illustrate not only the trustful patient-physician partnership in a threatening situation but also the high impact of state-of-the art recommendations by the respective scientific society."],"journal":"Z Rheumatol","authors":["Schmeiser, T","Broll, M","Dormann, A","Frabel, C","Hermann, W","Hudowenz, O","Keil, F","Muller-Ladner, U","Ozden, F","Pfeiffer, U","Saech, J","Schwarting, A","Stapfer, G","Steinchen, N","Storck-Muller, K","Strunk, J","Thiele, A","Triantafyllias, K","Wassenberg, S","Wilden, E","Hasseli, R"],"date":"2020-04-19T11:00:00Z","year":2020,"_id":"32303821","week":"202016|Apr 13 - Apr 19","doi":"10.1007/s00393-020-00800-8","keywords":["antirheumatic therapy","covid-19","patient questionnaire","rheumatic diesease"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664632934667124736,"score":55.884766},{"pmid":32205336,"title":"Are my patients with rheumatic diseases at higher risk of COVID-19?","text":["Are my patients with rheumatic diseases at higher risk of COVID-19?","Ann Rheum Dis","Figueroa-Parra, Gabriel","Aguirre-Garcia, Gloria Mayela","Gamboa-Alonso, Carmen Magdalena","Camacho-Ortiz, Adrian","Galarza-Delgado, Dionicio Angel","32205336"],"journal":"Ann Rheum Dis","authors":["Figueroa-Parra, Gabriel","Aguirre-Garcia, Gloria Mayela","Gamboa-Alonso, Carmen Magdalena","Camacho-Ortiz, Adrian","Galarza-Delgado, Dionicio Angel"],"date":"2020-03-25T11:00:00Z","year":2020,"_id":"32205336","week":"202013|Mar 23 - Mar 29","doi":"10.1136/annrheumdis-2020-217322","keywords":["DMARDs (biologic)","DMARDs (synthetic)","autoimmune diseases","epidemiology","infections"],"source":"PubMed","topics":["Prevention"],"weight":1,"_version_":1663352133719687168,"score":52.279545},{"pmid":32306656,"title":"[Clinical consideration and management of coronavirus disease 2019].","text":["[Clinical consideration and management of coronavirus disease 2019].","Coronavirus disease 2019 (COVID-19) outbreak in Wuhan city, Hubei province in December 2019 and the epidemic so rapidly happened within the whole country and abroad, raising serious problems and urgent concerns, such as: how to control most effectively human-to-human transmission? When does infection rate rise to its peak? What will eventually be the number of infected patients? How to make early diagnosis? What effective antiviral drugs are available? How to use the existing drugs to achieve the best effect? Can available drugs effectively improve the survival rate of critical patients? In view of the above questions, this article now puts forwards the corresponding suggestions and considerations from the perspective of clinical infectious diseases physician.","Zhonghua Gan Zang Bing Za Zhi","Ma, K","Chen, T","Han, M F","Guo, W","Ning, Q","32306656"],"abstract":["Coronavirus disease 2019 (COVID-19) outbreak in Wuhan city, Hubei province in December 2019 and the epidemic so rapidly happened within the whole country and abroad, raising serious problems and urgent concerns, such as: how to control most effectively human-to-human transmission? When does infection rate rise to its peak? What will eventually be the number of infected patients? How to make early diagnosis? What effective antiviral drugs are available? How to use the existing drugs to achieve the best effect? Can available drugs effectively improve the survival rate of critical patients? In view of the above questions, this article now puts forwards the corresponding suggestions and considerations from the perspective of clinical infectious diseases physician."],"journal":"Zhonghua Gan Zang Bing Za Zhi","authors":["Ma, K","Chen, T","Han, M F","Guo, W","Ning, Q"],"date":"2020-04-21T11:00:00Z","year":2020,"_id":"32306656","week":"202017|Apr 20 - Apr 26","doi":"10.3760/cma.j.cn50113-20200220-00056","keywords":["2019 novel coronavirus","covid-19","diagnosis","treatment"],"source":"PubMed","topics":["Prevention","Treatment","Diagnosis"],"weight":1,"locations":["Wuhan","Hubei"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664632501355675649,"score":50.420162}]}